5:34 PM
Oct 03, 2013
 |  BC Extra  |  Clinical News

Incyte reports first data for JAK-1 inhibitor INCB39110

Incyte Corp. (NASDAQ:INCY) presented Phase II data on Thursday at the European Academy of Dermatology and Venereology meeting from a double-blind, dose-escalation trial evaluating INCB39110, a Janus kinase-1 (JAK-1) inhibitor, to treat chronic plaque psoriasis. Oral INCB39110 reduced mean static Physician Global Assessment (sPGA) scores from baseline...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >